Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05048901 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Aug 31, 2026 to Aug 31, 2027
    • Study completion date: Dec 31, 2026 to Dec 31, 2027
    v4
  2. Primary completion date: Aug 31, 2025 to Aug 31, 2026
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 11
    • Start date changed from estimate of Sep 30, 2021 to Sep 17, 2021
    • Collaborators: 8 to 9
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an Open-Label Phase I/II Study of daily cabozantinib plus lanreotide every 4 w eeks to treat advanced G1-2 gastroentero-pancreatic neuroendocrine tumor (GEP-NET) patients who failed to one line or more than one line of small molecule kinase inhibitor or well-differentiated (W-D) G3 GEP-NET who failed to one line of small molecule kinase inhibitor or chemotherapy.
Trial Details
NCT Number NCT05048901
Lead Sponsor National Health Research Institutes, Taiwan
Collaborators: National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Tri-Service General Hospital (TSGH), Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital
Conditions
(from sponsor)		 Neuroendocrine Tumors,Gastroenteropancreatic
Related terms Neuroendocrine Tumors
Enrollment 49 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov